CMPS stock forecast, quote, news & analysis
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions... Show more
Why Compass Pathways (CMPS) Stock Is Up +26% in the Last 30 Days
Key Takeaways
- Compass Pathways shares advanced roughly 26% over the trailing 30 days, from an $11.26 close on July 24, 2026, to about $14.19.
- The rebound was driven by second-quarter 2026 results and continued progress on the rolling New Drug Application (NDA) for COMP360 psilocybin in treatment-resistant depression (TRD).
- Management reiterated plans to complete the NDA filing in Q4 2026, with a potential commercial launch in the first half of 2027.
- A cash position of $433.3 million as of June 30, 2026, provides an operating runway into 2028.
- Over the trailing three months, the stock is up about 20%, though trading has remained volatile around binary clinical and regulatory milestones.
Compass Pathways (CMPS) Company Overview and Market Position
Compass Pathways plc is a clinical-stage mental health biotechnology company headquartered in London, with a U.S. presence in New Jersey. Its lead asset, COMP360, is a proprietary, synthetic formulation of psilocybin under investigation for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). COMP360 has Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for TRD, as well as Innovative Licensing and Access Pathway designation in the U.K.
The company is running one of the largest classic psychedelic clinical programs in TRD, anchored by two pivotal Phase 3 trials, COMP005 and COMP006, which both met their primary endpoints with high statistical significance. Investors follow CMPS closely because COMP360 represents a potential first-in-class therapy in a condition with limited approved options, where existing treatments such as esketamine (Spravato, from Johnson & Johnson) require frequent clinic visits. The stock's risk profile reflects its pre-revenue status and the binary nature of regulatory decisions ahead.
Compass Pathways (CMPS) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, CMPS climbed approximately 26%, moving from an $11.26 close on July 24, 2026, to around $14.19 as of August 24, 2026. The advance was not linear: the stock pulled back to roughly $10.85 in late July before a sharp rally following the company's August 5 earnings report, which saw shares jump about 15% in a single session.
The broader quarterly trend has been similarly positive but more volatile. Measured from roughly three months earlier, when shares closed near $11.81 in late May, the stock is up about 20%. Within that period, CMPS traded as high as approximately $15.07 in late June and as low as about $10.59 intraday in late July, reflecting investor repositioning around clinical data and regulatory milestones rather than steady appreciation.
What Drove CMPS Stock Price in the Last 30 Days
The primary catalyst in the most recent 30-day window was the company's second-quarter 2026 financial results, reported on August 5. While the quarter's net loss of $253.8 million, or $1.88 per share, was wider than consensus, the reported loss was driven largely by a $205.6 million non-cash fair-value adjustment on warrants tied to the rising share price. Investors focused instead on the balance sheet and the regulatory timeline: cash and cash equivalents stood at $433.3 million as of June 30, 2026, and management confirmed the rolling NDA submission for COMP360 is underway, with final filing targeted for the fourth quarter of 2026.
Analyst activity also supported sentiment during the period. B. Riley raised its price objective to $22 with a Buy rating in early August, while Oppenheimer reaffirmed an Outperform rating and Compass Point set a $25 target in July. The consensus rating remains a Moderate Buy with an average price target near $23.36. These revisions, combined with management's messaging that the clinical and regulatory profile of COMP360 has been largely de-risked, underpinned the month's advance.
What Drove CMPS Stock Performance Over the Last Quarter
The quarterly move reflects a longer-running narrative of clinical validation and regulatory momentum. In early July, the company announced six-month (26-week) data from the COMP006 Phase 3 trial, confirming a rapid onset of effect and durable response through at least six months, with a generally well-tolerated safety profile. Together with the earlier COMP005 results, the data package forms the foundation of the NDA.
Broader factors have also shaped the quarterly trend. The company has accelerated commercial readiness, completing its commercial leadership team and beginning sales-force recruitment, and has expanded strategic collaborations to eight partners. At the same time, the stock's high beta and dependence on FDA and Drug Enforcement Administration (DEA) decisions have produced wide price swings, with profit-taking episodes offsetting rallies. The one-year gain of more than 200% reflects how far sentiment has shifted from the stock's earlier multi-year decline.
Trending AI Robots
For traders seeking a data-driven approach to volatile names like CMPS, Tickeron's Trending AI Robots page offers a curated view of its most relevant automated strategies. Tickeron provides hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most applicable bots are featured in this section. These robots vary by strategy, holding timeframe, and performance metrics, allowing users to compare approaches rather than relying on a single signal. The section is designed to help traders identify strategies that are currently in focus, and exploring the available robots can offer a useful complement to fundamental and technical research.
CMPS Stock Forecast Drivers: What Investors Should Watch Next
The most important near-term catalyst is the completion of the rolling NDA submission for COMP360, which the company expects in the fourth quarter of 2026. Investors are also watching for the FDA's review progress and any decision on potential accelerated approval, as well as the separate requirement that the DEA and individual states reschedule COMP360 before any U.S. commercial launch, which management currently anticipates in the first half of 2027.
Additional factors to monitor include the submission of full 52-week safety data, finalization of any Risk Evaluation and Mitigation Strategy (REMS) requirements, payer and reimbursement discussions, and the company's capital position as it transitions toward commercialization. Competitive developments in the psychedelic and psychiatric space, along with broader biotech sentiment and macroeconomic conditions, will also influence trading. These milestones carry meaningful uncertainty, and outcomes are not guaranteed.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CMPS in upward trend: 10-day moving average crossed above 50-day moving average on August 12, 2026
The 10-day moving average for CMPS crossed bullishly above the 50-day moving average on August 12, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 47 of 60 cases where CMPS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for CMPS just turned positive on September 09, 2026. Looking at past instances where CMPS's MACD turned positive, the stock continued to rise in 31 of 44 cases over the following month. The odds of a continued upward trend are 70%.
Following a +14.32% 3-day Advance, the price is estimated to grow further. Considering data from situations where CMPS advanced for three days, in 229 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
The Aroon Indicator entered an Uptrend today. In 174 of 204 cases where CMPS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CMPS as a result. In 68 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CMPS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
CMPS broke above its upper Bollinger Band on August 25, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. CMPS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (23.529) is normal, around the industry mean (238.721). P/E Ratio (0.000) is within average values for comparable stocks, (132.225). CMPS's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.624). CMPS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.014). P/S Ratio (0.000) is also within normal values, averaging (2.673).
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CMPS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry HospitalNursingManagement